Olympus today announced positive study data for its minimally invasive iTind treatment for the symptoms of enlarged prostate.
The iTind procedure involves the placement of a temporary implanted nitinol device that reshapes the prostatic urethra. It does this without burning or cutting the prostate. Device placement can occur in an outpatient setting or physician office.
Olympus’ device remains in place for five to seven days while the patient stays at home. Upon removal, patients experience rapid and effective relief of their symptoms. Olympus acquired iTind when it acquired Medi-Tate, now a wholly-owned subsidiary, in May 2021.
It offers an alternative to pharmaceutical therapy, plus surgeries and permanent implants. It’s proven to relieve symptoms without affecting sexual and ejaculatory function or urinary continence.
Results from a long-term study showed long-lasting relief of more than four years for people with an enlarged prosta…